Nasus Pharma Ltd(NSRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.33 | Insider Own | 49.21% | Shs Outstand | 11.7M | Perf Week | -0.34% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | 2.87% | Insider Trans | 0.11% | Shs Float | 6.0M | Perf Month | -7.91% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | 0 | Inst Own | 18.36% | Short Float | 1.19% | Perf Quarter | -9.06% |
| Income | -0.00B | P/S | - | EPS this Y | -55.14% | Inst Trans | -8.22% | Short Ratio | 4.09 | Perf Half Y | -3.96% |
| Sales | 0.00B | P/B | 9.23 | EPS next 5Y | 3.96% | ROA | -153.55% | Short Interest | 0.07M | Perf YTD | -68.2% |
| Book/sh | 0.32 | P/C | 8.52 | EPS past 3/5Y | -49.37% - | ROE | -278.36% | 52W High | -69.37% ($9.50) | Perf Year | -61.2% |
| Cash/sh | 0.34 | P/FCF | - | Sales past 3/5Y | - | ROIC | -90.35% | 52W Low | 46.97% ($1.98) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 6.82% 8.62% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.26 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.77 | EPS Q/Q | -358.03% | Profit Margin | - | RSI (14) | 38.58 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.77 | Sales Q/Q | - | SMA20 | -7.41% ($3.14) | Beta | 4.14 | Target Price | $16.5 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/17 | SMA50 | -14.67% ($3.41) | Rel Volume | 0.28 | Prev Close | $2.98 |
| Employees | 7 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | - | SMA200 | -16.96% ($3.5) | Avg Volume(3M) | 0.02M | Price | $2.91 |
| IPO | 2025/8/13 | Option/Short | No/Yes | Trades | 63 | Volume | 4,788 | Change | -2.51% |
Nasus Pharma is a clinical-stage biotechnology company headquartered in Tel Aviv, Israel, developing emergency and chronic therapeutic candidates based on its proprietary "Nasax" nasal powder delivery technology. Its lead pipeline candidate is NS002, a nasal-spray form of epinephrine (rather than an injection), aimed at replacing traditional injectable methods in the anaphylaxis emergency treatment market.
Over the past 1 year, on the lower side
69% below its 1-year high.
Traded less than usual. That is 28% of its average volume.
NSRX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -55.1% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 18.4%.
Tap to view numbers
It ranks #18 of 21 in the industry
Based on market cap of $34M.
AMRN#17 Amarin Corp ADR $247M PER - NSRX#18 Nasus Pharma Ltd $34M PER - 
MIRA#19 Mira Pharmaceuticals Inc $26M PER - 
SCLX#20 Scilex Holding Company $11M PER - 
MDCX#21 Medicus Pharma Ltd $3M PER - 
FAQ
What kind of company is NSRX?
NSRX belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of NSRX?
The market cap of NSRX is approximately $34M, ranking 5,009 within its sector.
What is the 52-week high and low for NSRX?
NSRX has recorded a 52-week high of $9.50 and a low of $1.98.
